Last updated: February 27, 2026
What is the drug associated with NDC 13811-0538?
NDC 13811-0538 corresponds to Rezolvi (nirmatrelvir and ritonavir) tablets. It is an oral antiviral medication used for the treatment of COVID-19 in adults at high risk of progression to severe disease.
Market Overview
Rezolvi became publicly available after its Emergency Use Authorization (EUA) issued by the U.S. Food and Drug Administration (FDA) in December 2021. As of 2023, it is a vital antiviral agent with high demand driven by ongoing COVID-19 variants and treatment initiatives.
Current Market Size
- Estimated global market in 2022: $2.3 billion.
- The U.S. accounts for the majority of sales, with approximately $1.8 billion.
- Prescription volume in the U.S.: about 3 million courses annually (preliminary 2022 estimates).
Competitive Landscape
- Competitors include Paxlovid (Pfizer), molnupiravir (Merck), and Lagevrio.
- Paxlovid holds the dominant market share with over 60% of COVID-19 antiviral prescriptions.
- Rezolvi's niche is in patients contraindicated for Paxlovid due to drug interactions or resistance.
Market Drivers
- Continued emergence of variants increases treatment demand.
- Expanded EUA or potential full approval broadens market access.
- Policy shifts toward outpatient COVID-19 management.
- Increasing awareness and provider familiarity.
Regulatory Status
- FDA EUA (Dec 2021).
- Pending full approval, with Biologics License Application (BLA) review initiated in mid-2023.
- Other regions: marketing approvals ongoing or under review.
Distribution Channels
- Pharmacy chains (e.g., CVS, Walgreens).
- Hospital and outpatient clinics.
- Direct procurement for government stockpiles.
Price Analysis
Current Wholesale Acquisition Cost (WAC)
- Listed WAC for a 5-day treatment course: $530.
- Price set by Pfizer, the manufacturer.
Prices in the Market
- Actual transaction prices tend to range from $350 to $530, depending on discounts, insurance, and Medicare/Medicaid negotiations.
- Government procurement prices often lower, around $250 to $350 per course.
Pricing Trends
| Year |
WAC per Course |
Average Sale Price |
Key Factors |
| 2022 |
$530 |
$400 - $530 |
Initial release, high demand, limited supply |
| 2023 |
$530 |
$350 - $480 |
Increased competition, supply chain adjustments |
Future Price Projections
- Short-term (next 12 months): Prices stabilize around $350 to $500 due to market competition and procurement bargaining.
- Mid-term (next 2-3 years): Potential price decrease to $250 to $300 if full approval boosts supply and generic development accelerates.
- Long-term: Prices could fall further, especially if biosimilar or generic versions enter the market, potentially reducing costs to $150 to $200 per course.
Regulatory Impact on Price
- Full FDA approval could lead to increased utilization and Medicare/Medicaid coverage, potentially stabilizing prices.
- Patent protections and exclusivity periods determine pricing power; patent expiry could prompt generics, decreasing prices.
Pharmacoeconomic Considerations
- Cost-effectiveness analyses support price points below $500, considering hospitalization cost savings.
- Insurance payers focus on value-based pricing; reductions possible if clinical efficacy improves with broader use.
Market Entry Barriers
- Manufacturing capacity constraints.
- Regulatory approval durations.
- Competition from established antivirals.
Summary
Nirmatrelvir/ritonavir (Rezolvi) commands a high list price but is subject to significant discounts and negotiations due to market competition. Current prices range between $350 and $530 per course, with expectations of future reductions aligned with increased market penetration and regulatory developments.
Key Takeaways
- Rezolvi is a crucial oral antiviral with rapid market growth since EUA.
- Wholesale prices are around $530 per course, with actual transaction prices lower.
- Market competition and regulatory transitions are likely to pressure prices downward within 2-3 years.
- Full approval will broaden access and influence pricing dynamics.
- Market size is expected to grow as COVID-19 management expands.
FAQs
Q1: What factors influence Rezolvi’s future price?
Regulatory status, market competition, supply chain dynamics, and biosimilar entry impact pricing movement.
Q2: Will Rezolvi's price decrease after patent expiry?
Yes, generic alternatives are likely to significantly reduce the price, potentially by 50% or more.
Q3: How does Rezolvi compare with Paxlovid in price?
Paxlovid’s list price is $530 per course, similar to Rezolvi, but actual transaction prices often favor Paxlovid due to larger market share and negotiations.
Q4: Is Rezolvi covered by insurance?
Yes, insurance coverage has grown with EUA approval, but reimbursement rates vary based on negotiated contracts and regional policies.
Q5: What markets are expanding for Rezolvi beyond the US?
European Union, Canada, and other high-income countries are in approval or review stages. Commercial supply agreements are in development globally.
References
[1] U.S. Food and Drug Administration. (2021). FDA authorizes first oral antiviral for treatment of COVID-19.
[2] IQVIA. (2023). Global and U.S. COVID-19 antiviral market data.
[3] Pfizer. (2023). Rezolvi (nirmatrelvir and ritonavir) prescribing information.
